Share on StockTwits

Shares of Nektar Therapeutics (NASDAQ:NKTR) have received a consensus recommendation of “Buy” from the ten brokerages that are covering the stock, Analyst RN reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $16.00.

Nektar Therapeutics (NASDAQ:NKTR) traded up 0.21% on Wednesday, hitting $14.51. The stock had a trading volume of 150,718 shares. Nektar Therapeutics has a one year low of $8.87 and a one year high of $15.34. The stock’s 50-day moving average is $12.46 and its 200-day moving average is $12.41. The company’s market cap is $1.847 billion.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, July 31st. The company reported ($0.26) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.37) by $0.11. The company had revenue of $28.50 million for the quarter, compared to the consensus estimate of $19.76 million. During the same quarter in the prior year, the company posted ($0.37) earnings per share. The company’s quarterly revenue was down 15.9% on a year-over-year basis. On average, analysts predict that Nektar Therapeutics will post $-0.65 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on NKTR shares. Analysts at Roth Capital reiterated a “buy” rating on shares of Nektar Therapeutics in a research note on Thursday, August 21st. Finally, analysts at Zacks reiterated an “underperform” rating on shares of Nektar Therapeutics in a research note on Monday, August 4th. They now have a $11.00 price target on the stock.

Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms.

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.